CASTRES, France–(BUSINESS WIRE)–Pierre Fabre today announced interim analysis results from the Phase 3 BEACON CRC trial evaluating the combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor, and ERBITUX® (cetuximab), an anti-EGFR antibody (encorafenib Triplet), in patients with advanced BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two lines of therapy. Results showed that patients with BRAF-mutant mCRC treated with the encorafenib Triplet combinat

Source link